Loading...
•
Dec 31, 2021
Evofem Biosciences Q4 2021 Earnings Report
Evofem Biosciences experienced strong growth, with net product sales more than doubling in Q4 2021 and net cash burn decreasing.
Key Takeaways
Evofem Biosciences reported a strong fourth quarter, driven by a 109% increase in net product sales compared to the previous quarter. The company also reduced its net cash burn rate and completed enrollment in a Phase 3 trial for Phexxi.
Net product sales increased 109% to $3.6 million in the fourth quarter of 2021.
Net cash burn rate decreased to $16.8 million in the fourth quarter of 2021.
Enrollment completed in Phase 3 trial of Phexxi for prevention of chlamydia and gonorrhea in women.
Secured a $50 million equity line of credit.
Evofem Biosciences
Evofem Biosciences
Evofem Biosciences Revenue by Segment
Revenue by Segment
Net Product Sales Revenue
CapyFin.com Forward Guidance
Evofem Biosciences is focused on the ongoing development of Phexxi and future growth of sales of Phexxi and the Company generally.